Comparison of Gemphire Therapeutics Inc. (GEMP) and Aratana Therapeutics Inc. (NASDAQ:PETX)

As Biotechnology companies, Gemphire Therapeutics Inc. (NASDAQ:GEMP) and Aratana Therapeutics Inc. (NASDAQ:PETX) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemphire Therapeutics Inc. N/A 0.00 26.73M -2.11 0.00 Aratana Therapeutics Inc. 40.96M 5.07 21.69M -0.51 0.00 Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Gemphire Therapeutics Inc. and Aratana Therapeutics Inc.

Profitability

Table 2 represents Gemphire Therapeutics Inc. (NASDAQ:GEMP) and Aratana Therapeutics Inc. (NASDAQ:PETX)’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Gemphire Therapeutics Inc. 0.00% -211% -99.4% Aratana Therapeutics Inc. -52.95% -23% -16.1% Liquidity

The Current Ratio of Gemphire Therapeutics Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival Aratana Therapeutics Inc. is 3.2 and its Quick Ratio is has 2.7. Gemphire Therapeutics Inc. is better equipped to clear short and long-term obligations than Aratana Therapeutics Inc.

Analyst Recommendations

Gemphire Therapeutics Inc. and Aratana Therapeutics Inc. Recommendations and Ratings are available on the next table.

Competitively the average target price of Aratana Therapeutics Inc. is $5, which is potential 17.10% upside.

Insider and Institutional Ownership

The shares of both Gemphire Therapeutics Inc. and Aratana Therapeutics Inc. are owned by institutional investors at 28.1% and 68.4% respectively. Insiders owned 23.61% of Gemphire Therapeutics Inc. shares. Insiders Competitively, owned 2% of Aratana Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Gemphire Therapeutics Inc. -9.4% -24.82% -49.76% -83.74% -86.36% -86.66% Aratana Therapeutics Inc. -2.77% -9.33% 22.48% 25.15% 16.39% 20.15% For the past year Gemphire Therapeutics Inc. has -86.66% weaker performance while Aratana Therapeutics Inc. has 20.15% stronger performance.

Summary

Aratana Therapeutics Inc. beats on 8 of the 10 factors Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Tags:

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *